Overview of Combination Product Development for Pulmonary Drug Delivery 2013

Topics

• Commercial Development Status (Non-respiratory Conditions)
• Pulmonary Generic Product Space
• Architecture of the Lungs
• Pulmonary Deposition and Comparison of Technologies
• Inhalation Devices and Lung Biology
• Physical Characterization (including Engineered Dry Powders)
• Rationales for Reimbursement
• Comparison of Oral vs Inhaled Drug Product Development
• Conclusions and Recommendations

Who should Attend

Attendees from medical device and pharma/biopharma companies, including:

• Regulatory affairs
• Senior management
• CMC and Clinical Development
• Quality Assurance